Brief: Aligos Therapeutics Inc Says It Files A Response To Complaint Of, And Counterclaims Against, Janssen Biopharma
29/09/2022 10:39
Sept 29 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS INC - FILED A RESPONSE TO COMPLAINT
OF, AND
COUNTERCLAIMS AGAINST, JANSSEN BIOPHARMA
* ALIGOS THERAPEUTICS - FILED A RESPONSE TO COMPLAINT OF,
AND
COUNTERCLAIMS AGAINST, JANSSEN IN CALIFORNIA STATE SUPERIOR
COURT FOR COUNTY OF SAN MATEO
* ALIGOS THERAPEUTICS INC - RESPONSE FURTHER OUTLINES AND
DOCUMENTS THAT ALL WORK WAS PERFORMED BY ALIGOS EMPLOYEES AFTER
LEAVING JANSSEN BIOPHARMA
* ALIGOS THERAPEUTICS INC - COUNTERCLAIMS AGAINST JANSSEN
ALLEGE
THAT JANSSEN HAS ENGAGED IN "UNFAIR COMPETITION AND PROMISSORY
FRAUD"
Source text for Eikon: ID:nGNX72GVJL
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue